BR0107705A - Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva - Google Patents

Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva

Info

Publication number
BR0107705A
BR0107705A BR0107705A BR0107705A BR0107705A BR 0107705 A BR0107705 A BR 0107705A BR 0107705 A BR0107705 A BR 0107705A BR 0107705 A BR0107705 A BR 0107705A BR 0107705 A BR0107705 A BR 0107705A
Authority
BR
Brazil
Prior art keywords
blood
patient
heart failure
congestive heart
aliquot
Prior art date
Application number
BR0107705A
Other languages
English (en)
Inventor
Eldon R Smith
Guillermo Torre-Amione
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of BR0107705A publication Critical patent/BR0107705A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

"USO DE UMA ALìQUOTA DE SANGUE MODIFICADO EM UM PACIENTE PARA TRATAMENTO DE FALêNCIA CARDìACA CONGESTIVA". Um método para tratar falência cardíaca congestiva (CHF) em um paciente humano compreende o tratamento de uma alíquota de sangue do paciente ex vivo com pelo menos um elemento de stress selecionado do grupo que consiste em uma temperatura acima ou abaixo da temperatura corpórea, uma emissão eletromagnética e um ambiente oxidativo, seguido pela administração da alíquota de sangue tratado ao paciente. O tratamento pode ser usado isoladamente ou em terapia combinada com tratamentos para CHF convencionais.
BR0107705A 2000-01-18 2001-01-18 Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva BR0107705A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2296997 CA2296997A1 (en) 2000-01-18 2000-01-18 Treatment of congestive heart failure
PCT/CA2001/000039 WO2001052870A1 (en) 2000-01-18 2001-01-18 Treatment of congestive heart failure by pretreated autologous blood

Publications (1)

Publication Number Publication Date
BR0107705A true BR0107705A (pt) 2002-11-19

Family

ID=4165156

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107705A BR0107705A (pt) 2000-01-18 2001-01-18 Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva

Country Status (24)

Country Link
US (3) US6572895B2 (pt)
EP (1) EP1267897B1 (pt)
JP (1) JP2003520244A (pt)
KR (1) KR100543413B1 (pt)
CN (1) CN1173710C (pt)
AT (1) ATE281839T1 (pt)
AU (1) AU773118B2 (pt)
BR (1) BR0107705A (pt)
CA (2) CA2296997A1 (pt)
CZ (1) CZ20022402A3 (pt)
DE (1) DE60107065T2 (pt)
DK (1) DK1267897T3 (pt)
EA (1) EA005011B1 (pt)
ES (1) ES2232632T3 (pt)
HK (1) HK1050847B (pt)
IL (1) IL150725A0 (pt)
MX (1) MXPA02007032A (pt)
NO (1) NO20023267L (pt)
NZ (1) NZ520083A (pt)
PL (1) PL357261A1 (pt)
PT (1) PT1267897E (pt)
TR (1) TR200201822T2 (pt)
WO (1) WO2001052870A1 (pt)
ZA (1) ZA200205401B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040199209A1 (en) * 2003-04-07 2004-10-07 Hill Michael R.S. Method and system for delivery of vasoactive drugs to the heart prior to and during a medical procedure
US6628987B1 (en) * 2000-09-26 2003-09-30 Medtronic, Inc. Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia
US6904318B2 (en) * 2000-09-26 2005-06-07 Medtronic, Inc. Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure
US8036741B2 (en) 1996-04-30 2011-10-11 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US6449507B1 (en) * 1996-04-30 2002-09-10 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
US7269457B2 (en) * 1996-04-30 2007-09-11 Medtronic, Inc. Method and system for vagal nerve stimulation with multi-site cardiac pacing
US6479523B1 (en) * 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
CA2376903A1 (en) * 1999-06-25 2001-01-04 Emory University Devices and methods for vagus nerve stimulation
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
AU2001278844A1 (en) * 2000-04-26 2001-11-07 Herzel Laor Configuring optical fibers in a multi-chip module
US6487446B1 (en) * 2000-09-26 2002-11-26 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
CA2327631A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Inflammatory cytokine secretion inhibition
CN1652831A (zh) * 2002-04-10 2005-08-10 费梭根爱尔兰有限公司 慢性心力衰竭治疗的心电图特点
US7255880B2 (en) * 2003-04-03 2007-08-14 Vasogen Ireland Limited Treatment of endothelin-related disorders
US20100318014A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of acute ischemic brain stroke with ozone
US20100316727A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of inflammatory disorders with ozone
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
US20060095102A1 (en) * 2003-09-17 2006-05-04 Thomas Perez Method and apparatus for sublingual application of light to blood
US20050100964A1 (en) * 2003-11-11 2005-05-12 George Jackowski Diagnostic methods for congestive heart failure
WO2005097145A1 (en) * 2004-04-12 2005-10-20 Vasogen Ireland Limited Myocarditis treatment
WO2008000067A1 (en) * 2006-06-26 2008-01-03 Vasogen Ireland Limited Treatment of mild chronic heart failure in human patients
CA2679178A1 (en) * 2007-02-26 2008-09-04 Mount Sinai Hospital Compositions and methods for treating peripheral vascular diseases
US8200308B2 (en) * 2007-07-18 2012-06-12 Siemens Medical Solutions Usa, Inc. Continuous measurement and mapping of physiological data
CN102802643A (zh) * 2009-06-19 2012-11-28 阿奎赛公司 利用臭氧治疗炎性病症、心血管疾病和急性缺血性脑中风
CA2765479A1 (en) * 2009-06-19 2010-12-23 Acquisci, Inc. Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
US8888699B2 (en) 2010-04-29 2014-11-18 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8639327B2 (en) 2010-04-29 2014-01-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8620425B2 (en) 2010-04-29 2013-12-31 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
CN101829372A (zh) * 2010-05-11 2010-09-15 江苏中惠医疗科技股份有限公司 血细胞凋亡诱导系统
CN101843931A (zh) * 2010-05-19 2010-09-29 江苏中惠医疗科技股份有限公司 一种血细胞凋亡诱导方法
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
ITMI20120338A1 (it) * 2012-03-06 2013-09-07 Dr Andrea Bignotti Preparato terapeutico e procedimento di preparazione di detto preparato terapeutico
CN113057965B (zh) * 2021-03-31 2023-07-04 河北康腾生物科技有限公司 一种活化焕颜美容液及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591457A (en) * 1992-02-07 1997-01-07 Vasogen Inc Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
EP0680346B1 (en) * 1992-02-07 2002-07-03 Vasogen Inc. Method of increasing the concentration of nitric oxide in blood
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6136308A (en) * 1997-09-12 2000-10-24 Vasogen Ireland Limited Treatment of stress and preconditioning against stress
WO1999013890A1 (en) 1997-09-12 1999-03-25 Vasogen Ireland Limited Treatment of stress and preconditioning against stress
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6422462B1 (en) * 1998-03-30 2002-07-23 Morris E. Cohen Apparatus and methods for improved credit cards and credit card transactions
CA2271190A1 (en) 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
US7627531B2 (en) * 2000-03-07 2009-12-01 American Express Travel Related Services Company, Inc. System for facilitating a transaction

Also Published As

Publication number Publication date
US6572895B2 (en) 2003-06-03
ATE281839T1 (de) 2004-11-15
MXPA02007032A (es) 2003-09-22
AU773118B2 (en) 2004-05-20
HK1050847A1 (en) 2003-07-11
CA2400801A1 (en) 2001-07-26
EA005011B1 (ru) 2004-10-28
TR200201822T2 (tr) 2003-01-21
CN1400906A (zh) 2003-03-05
NZ520083A (en) 2002-12-20
PL357261A1 (en) 2004-07-26
DE60107065T2 (de) 2005-04-07
WO2001052870A1 (en) 2001-07-26
US20030044390A1 (en) 2003-03-06
AU2820801A (en) 2001-07-31
NO20023267D0 (no) 2002-07-05
PT1267897E (pt) 2005-02-28
US7153649B2 (en) 2006-12-26
US20060193835A1 (en) 2006-08-31
EA200200767A1 (ru) 2002-12-26
EP1267897B1 (en) 2004-11-10
EP1267897A1 (en) 2003-01-02
CA2400801C (en) 2007-01-09
KR20020073506A (ko) 2002-09-26
CN1173710C (zh) 2004-11-03
NO20023267L (no) 2002-08-29
HK1050847B (zh) 2005-04-01
JP2003520244A (ja) 2003-07-02
IL150725A0 (en) 2003-02-12
KR100543413B1 (ko) 2006-01-20
ZA200205401B (en) 2003-07-07
CZ20022402A3 (cs) 2003-01-15
ES2232632T3 (es) 2005-06-01
US20020051766A1 (en) 2002-05-02
DE60107065D1 (de) 2004-12-16
CA2296997A1 (en) 2001-07-18
DK1267897T3 (da) 2005-02-14

Similar Documents

Publication Publication Date Title
BR0107705A (pt) Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
PT933995E (pt) Metodo para tratamento de lesao endotelial
DE69116380T2 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
IL138290A0 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
AU2251302A (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
PT1251850E (pt) Utilizacao de uma preparacao de combinacao na terapia do cancro
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
WO2001022976A3 (en) Combination of a statin and ex-vivo treated blood for treating artheroclerosis
RU97101420A (ru) Способ лечения тонзиллита
Muguruma et al. Chyluria treated with inguinal lymphangiovenous and lymph node-venous anastomosis: a case report
UA41150A (uk) Спосіб лікування критичної ішемії нижніх кінцівок
UA28400A (uk) Спосіб лікування мікробної екземи
KR20000016317U (ko) 원적외선과 자장을 이용한 생리통 경감팬티
RU98113451A (ru) Способ лечения аллергодерматозов
EA200000021A1 (ru) Способ коррекции физиологического состояния органов и систем живого существа
TNSN03022A1 (en) Method for treatment of inflammation
UA32153A (uk) Спосіб формування трансплантату для зведення на промежину при черевно-анальних резекціях прямої кишки
UA38301A (uk) Спосіб лікування облітеруючих захворювань судин кінцівок
UA30295A (uk) Спосіб лікування захворювань передміхурової залози
UA42274A (uk) Спосіб профілактики та лікування функціональних розладів організму пацієнта
UA28928A (uk) Спосіб лікування гнійно-запальних захворювань м'яких тканин

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A E 11A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.